Astex Pharmaceuticals, Inc., formerly SuperGen, Inc. is a pharmaceutical company. The Company is primarily engaged in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. The Company is developing a pipeline of medicines for partnership with pharmaceutical companies. It is also engaged in the application of fragment-based drug discovery and development of small-molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, Astex Therapeutics Limited, a wholly owned subsidiary, has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. In October 2013, Otsuka Holdings Co Ltd announced that its wholly owned subsidiary, Otsuka Pharmaceutical Co., Ltd completed, through its wholly owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:SUPG
CUSIPN/A
Phone+1-925-5600100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Astex Pharmaceuticals (NASDAQ:SUPG) Frequently Asked Questions
What is Astex Pharmaceuticals' stock symbol?
Astex Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPG."
What is the consensus analysts' recommendation for Astex Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astex Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Astex Pharmaceuticals been receiving favorable news coverage?
Media headlines about SUPG stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Astex Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave headlines about the healthcare company an impact score of 47.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Astex Pharmaceuticals?
Shares of SUPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Astex Pharmaceuticals?
Astex Pharmaceuticals' mailing address is Suite 200, 4140 Dublin Blvd., DUBLIN, CA 94568, United States. The healthcare company can be reached via phone at +1-925-5600100.
MarketBeat Community Rating for Astex Pharmaceuticals (NASDAQ SUPG)
MarketBeat's community ratings are surveys of what our community members think about Astex Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
